Merck has acquired AmpTec, a Hamburg, Germany-based, mRNA contract development and manufacturing organisation (CDMO), expanding its mRNA capabilities for vaccines, treatments and diagnostics.
The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in COVID-19 and many other diseases.
“The success of mRNA-based vaccines for COVID-19 lays the path to accelerate the development of these therapeutics for many other diseases,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
“By combining AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing, we are able to provide a truly differentiated and integrated offering across the mRNA value chain, which will significantly decrease supply chain complexity and enhance speed-to-market.
“This transaction is another important step to support the constant growth of our Life Science business through tailored, small-scale acquisitions with high impact.”
In addition to specialising in mRNA technology, AmpTec has a diagnostics business that focuses on producing customized long RNAs and DNAs for in vitro diagnostics.
It will complement Merck’s diagnostics business, which specializes in providing critical raw materials, components and services for in vitro diagnostics manufacturers.
Merck’s molecular materials portfolio includes custom and predesigned DNA oligos and probes for a variety of applications such as PCR, next generation sequencing and microarray production.
Merck is continuing to invest in mRNA as a modality and will scale up this technology both at AmpTec’s existing site in Hamburg and at Merck’s global headquarters in Darmstadt, Germany.
Financial terms were not disclosed.